Given the relatively high prevalence of TP53-germline mutations in patients with ACC and the high frequency of de novo mutations, genetic testing for TP53 mutations should be recommended for all, even in the absence of a positive family history (4, 5). This evidence concerns the gene TP53 and adrenal cortex carcinoma.